Compounded Semaglutide vs Brand-Name Wegovy: Risk and Cost Trade-offs
Compounded semaglutide became widely available during the 2023-2024 shortage and has been substantially restricted since. Here's where the regulatory landscape stands now, what compounded versions actually are, and the honest cost-vs-risk analysis.
The 60-second version
Compounded semaglutide is preparation by compounding pharmacies rather than purchase of FDA-approved Wegovy from Novo Nordisk. During the 2023-2024 shortage, compounding pharmacies supplied substantial quantities at lower cost. The FDA's 2024-2025 declarations that the shortage had resolved closed most compounding pathways. Compounded semaglutide remains available through some pathways but is regulatorily constrained and quality varies. The trade-off: compounded versions are 30-70% cheaper but carry identity, purity, and quality-control risks. Brand-name when accessible; legitimate compounding only with careful vendor diligence.
Key takeaways
- Compounded semaglutide is preparation by compounding pharmacies rather than Novo Nordisk's brand-name Wegovy.
- 2023-2024 shortage substantially expanded compounding; 2024-2025 FDA resolution closed most pathways.
- Brand-name Wegovy: FDA-approved quality, $900-1,400/month cash.
- Compounded semaglutide: typically $200-500/month, quality varies substantially.
- Quality concerns include dose variation, unapproved salt forms, endotoxin contamination.
- High-quality compounding produces pharmacologically equivalent product.
- Brand-name is lowest-risk; legitimate compounding is reasonable when unaffordable.
- Avoid grey-market sources — cost savings come with substantial quality risk.
What 'compounded' actually means
Compounding pharmacies prepare medications customized for individual patients. The legal framework distinguishes 503A pharmacies (traditional compounding for specific patients with specific prescriptions) and 503B outsourcing facilities (larger-scale compounding requiring more rigorous controls). Compounded semaglutide is the active molecule prepared by these pharmacies rather than Novo Nordisk. The molecule itself can be identical if properly prepared; supply chain and quality controls differ.
The 2023-2024 shortage and how compounding expanded
FDA shortage rules allow compounding pharmacies to prepare versions of drugs on the FDA shortage list. The 2022-2024 GLP-1 shortage opened this pathway substantially. Compounded semaglutide became widely available through compounding pharmacies, telehealth platforms, wellness clinics, and weight-loss programs. Cash pricing typically 50-70% below brand-name. Quality varied substantially across vendors.
The 2024-2025 regulatory resolution
The FDA declared the semaglutide shortage resolved in late 2024. 503A pharmacies could no longer compound under shortage rules. 503B outsourcing facilities had transition deadlines. Cease-and-desist letters issued to telehealth platforms continuing to dispense compounded versions.
Current 2026 landscape: more constrained but not fully closed. Some compounding through patient-specific medical necessity arguments. Some grey-market and international sources operating. Many former telehealth providers moved to alternative GLP-1 sourcing.
Quality variation
Concerns aren't theoretical. Independent testing of compounded products has documented: dose variation (some samples substantially less or more than labeled), salt forms (some products used semaglutide salts not approved for human use), endotoxin contamination (documented in some samples), stability issues (degraded peptide content from storage problems). Higher-quality compounding pharmacies produce pharmacologically equivalent product; lower-quality operations vary. Consumers typically can't distinguish high-quality from low-quality by exterior signals alone.
The cost dimension
Approximate 2026 pricing: Brand-name Wegovy $900-1,400/month cash; brand-name Ozempic similar range; compounded semaglutide $200-500/month through legitimate channels; telehealth/wellness clinic compounded $300-700/month; grey-market sources $50-200/month with higher quality risk. For uninsured patients, the access difference between $200/month compounded and $1,200/month brand-name is the difference between treatment access and no treatment.
The honest risk-vs-cost analysis
Brand-name Wegovy through legitimate insurance/manufacturer programs is the lowest-risk option. Compounded semaglutide from a high-quality pharmacy with full physician oversight, third-party quality testing, and established practice can be reasonable when brand-name is unaffordable. Verify: third-party purity certificates, approved semaglutide base (not salts), state pharmacy licensing in good standing, physician involvement, sterility certifications.
Telehealth-platform compounded sits in a middle tier — convenience and lower cost but variable quality. Grey-market and international sources carry highest risk and lowest price.
Practical recommendation
Check brand-name Wegovy coverage through insurance first. If unaffordable, identify a legitimate compounding pharmacy with proper licensing and third-party testing — typically $200-500/month range. Avoid the cheapest options ($50-100/month from unverified sources is where quality problems concentrate). Maintain clinical oversight regardless of source — labs, side-effect tracking, dose adjustment.
Frequently asked questions
Is compounded semaglutide the same as Wegovy?
It can be, when properly prepared. Active molecule is the same. Differences are in manufacturing source, quality controls, and regulatory oversight.
Is compounded semaglutide still legal in 2026?
Mostly restricted. FDA's 2024-2025 shortage resolution closed most 503A and 503B compounding pathways. Some compounding continues through specific medical-necessity arguments.
How can I tell if a compounded source is legitimate?
Look for: state pharmacy licensing in good standing, third-party purity certificates, approved semaglutide base (not salts), physician oversight, sterility certifications.
Will compounded semaglutide work as well as Wegovy?
If properly prepared, yes. If quality control is poor, no — underdosed or contaminated product won't produce equivalent results.
Is compounded tirzepatide available?
Tirzepatide shortage resolved earlier than semaglutide; compounded tirzepatide availability has been more restricted for longer.
References
- FDA. Drug shortages: GLP-1 receptor agonists status updates (2024-2025). https://www.accessdata.fda.gov/scripts/drugshortages/
- FDA. 503A and 503B compounding under sections of the FDCA. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
We update articles as new trials publish and the evidence base evolves. Last reviewed: May 2026.